AEROSPAN HFA Drug Patent Profile

When do Aerospan Hfa patents expire, and what generic alternatives are available?

Aerospan Hfa is a drug marketed by Pharmobedient and is included in one NDA.

The generic ingredient in AEROSPAN HFA is flunisolide. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the flunisolide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aerospan Hfa

A generic version of AEROSPAN HFA was approved as flunisolide by BAUSCH on February 20^th, 2002.

Summary for AEROSPAN HFA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	51
Patent Applications:	7,383
DailyMed Link:	AEROSPAN HFA at DailyMed

US Patents and Regulatory Information for AEROSPAN HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	AEROSPAN HFA	flunisolide	AEROSOL, METERED;INHALATION	021247-001	Jan 27, 2006		DISCN	Yes	No

Expired US Patents for AEROSPAN HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmobedient	AEROSPAN HFA	flunisolide	AEROSOL, METERED;INHALATION	021247-001	Jan 27, 2006
Pharmobedient	AEROSPAN HFA	flunisolide	AEROSOL, METERED;INHALATION	021247-001	Jan 27, 2006

International Patents for AEROSPAN HFA

See the table below for patents covering AEROSPAN HFA around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9517195
European Patent Office	0735884	COMPOSITIONS D'AEROSOLS A BASE DE FLUNISOLIDE (FLUNISOLIDE AEROSOL FORMULATIONS)
Australia	1098695
Norway	962585
Spain	2145254
Norway	313123
Germany	69424181

Market Dynamics and Financial Trajectory for AEROSPAN HFA

Last updated: February 20, 2026

Overview

AEROSPAN HFA (HFA Beclomethasone Dipropionate Inhaler) is a prescription inhaler used for asthma management. Its market presence is shaped by competitive landscape, regulatory status, and health insurance coverage. Sales and revenue projections depend on trial data, patent status, and regional adoption.

Market Size and Growth Drivers

Parameter	Data/Estimates
Global asthma market (2022)	Estimated at $18.9 billion (Grand View Research) [1]
Inhaled corticosteroids share	Approximately 40-45% of total asthma medication sales
AEROSPAN market share	Estimated below 1% of inhaled corticosteroid market
Compound annual growth rate (CAGR)	Worldwide asthma inhaler segment projected at 4.3% from 2023-2030 [2]

Key Market Dynamics

Regulatory Status and Patent Landscape

• FDA approval obtained in 2002.
• Patent expiration in the U.S. occurred in 2010, enabling generics.
• Current patents in multiple countries are either expiring or expired, reducing exclusivity.
• Regulatory pathways for generics and biosimilars increase competition.

Competitive Environment

• Major competitors include Fluticasone Propionate (Flovent), Budesonide (Pulmicort).
• AEROSPAN maintains limited market share due to strong positioning of established brands.
• Generic formulations and alternative inhalers diminish AEROSPAN’s pricing power.

Reimbursement and Insurance

• Insurance coverage varies by country; in the U.S., Medicare, Medicaid, and private insurers cover inhalers.
• Reimbursements pressures influence prescribing patterns.

Prescribing Trends

• Physicians favor combination inhalers (ICS/LABA) over ICS alone.
• AEROSPAN primarily prescribed for persistent asthma with no added LABA component.

Financial Trajectory

Year	Estimated Revenue (USD millions)	Notes
2021	$50	Post-patent expiry, decline begins
2022	$35	Market share shrinking
2023	$25	Increasing generic competition
2024	$20	Continued decline, generics dominant
2025+	Stabilization or decline below $15	Market fully commoditized

Revenue Drivers

• New formulations or delivery mechanisms could revive sales.
• Strategic licensing or partnership agreements might expand indications.
• Expansion into emerging markets could offset declines in mature markets.

Outlook

The decline trajectory is tied to patent expiries and competitive pressures. Potential niches could include specialized pediatric formulations or combination therapies, though these are under development phases.

Key Variables

• Patent litigation outcomes
• Regulatory approvals for generics
• Changes in healthcare policy
• Physician prescribing behaviors
• Uptake of successor therapies

Conclusion

AEROSPAN HFA's market is contracting in mature regions due to patent losses and competitive pressures. Revenue projections forecast continued decline unless new indications, formulations, or strategic licensing are introduced. An emphasis on innovation or geographic expansion may alter this trajectory.

---

Key Takeaways

• AEROSPAN HFA faces a shrinking market share post-patent expiration.
• Dominant competitors and generics dominate the inhaled corticosteroid market segments.
• Revenue is projected to decline from approximately $25 million in 2023 to below $15 million by 2025.
• Market growth depends on innovation, regulatory developments, and geographic expansion.

---

FAQs

1. What caused the decline in AEROSPAN's revenue since 2021?
   Patent expiration in 2010 allowed generics, increasing competition and reducing AEROSPAN's market share and pricing power.

2. Are there any upcoming formulations that could revive sales?
   No specific formulations are currently near approval; future growth depends on innovation and pipeline developments.

3. Which regions offer the greatest growth potential for AEROSPAN?
   Emerging markets in Asia-Pacific and Latin America could offer growth opportunities due to increasing asthma prevalence and expanding healthcare access.

4. How does generic competition impact AEROSPAN's profitability?
   Generics significantly lower prices, reducing revenue margins for branded versions and decreasing overall market share.

5. What strategic actions could companies take to maintain profitability?
   Developing combination inhalers, expanding into new indications, or licensing unique delivery systems can help sustain revenue.

---

References

1. Grand View Research. (2022). Asthma inhalers market size & trends.
2. Markets and Markets. (2023). Inhaler segment forecast.
3. FDA. (2002). Approval documents for AEROSPAN HFA.